| 产品描述: | PG01 是一种有效的 CFTR Cl- 通道增效剂。PG01 对 E193K,G970R 和 G551D (CFTR突变体) 有效,Kd 值分别为 0.22 μM,0.45 μM 和 1.94 μM。PG01对 ΔF508(Ka 为 0.3 μM)也有效。PG01 在添加 Forskolin 后增加 ΔF508-CFTR Cl- 电流。 |
| 靶点: |
CFTR |
| 体外研究: |
PG01 itself does not activate ∆F508-CFTR, produces substantial ∆F508-CFTR Cl- current after the addition of 0.5 and 2 μM Forskolin. PG01 at 100 nM strongly stimulates channel activity with multiple channel openings observed. The apparent Kd for PG01 for G551D-CFTR activation is 1 μM, approximately 100-fold better than that of genistein. The potency for activation G1349D-CFTR by PG01 is even better at 40 nM. PG01 produces large currents in both G551D- and G1349D-CFTR expressing cells. The currents are sensitive to CFTRinh-172 and are not seen in nontransfected cells. |
| 体内研究: |
Pharmacokinetic analysis of PG01 in rats is done by serial measurements of plasma concentrations after single bolus infusions (5 mg/kg). PG01 pharmacokinetics fitted a two-compartment model with half-times of <5 min and 130 min with volume of distribution 4 L. Microsome metabolism studies and rat pharmacokinetic analysis suggests significantly more rapid metabolism of PG01 than SF-03. |
| 参考文献: |
1. Pedemonte N, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol. 2005 May;67(5):1797-807.
2. Caputo A, et al. Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators. J Pharmacol Exp Ther. 2009 Sep;330(3):783-91. |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.275 ml |
11.375 ml |
22.75 ml |
| 5 mM |
0.455 ml |
2.275 ml |
4.55 ml |
| 10 mM |
0.228 ml |
1.138 ml |
2.275 ml |
| 50 mM |
0.046 ml |
0.228 ml |
0.455 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |